Abstract:Introduction Cognitive impairment is prevalent and pronounced among people with schizophrenia (PwS). These individuals experience a large disability and financial burdens. Annually, US costs estimate roughly $87,000 per PwS, largely related to cognitive deficits and associated disability. Risk factors for poor cognition may include older age and female sex. For PwS, illness-specific risks may include severity of positive and negative symptoms, and antipsychotic and anticholinergic use. Thus, our aim is to assess susceptibility and risks in this population in order to target therapy, improve outcomes, enhance quality of life, and lower costs. We hypothesize that poor cognition will be associated with older age and female sex for both non psychiatric comparison (NC) and PwS groups. For PwS, we hypothesize that poor cognition will be associated with more severe positive and negative symptoms, as well as with greater antipsychotic dosage and anticholinergic use. Methods We performed a cross-sectional analysis on 155 participants (51% were female) recruited from the San Diego area via flyering, outreach, and word of mouth. They range between 26 to 65 years of age. Of this sample, 92 participants met the DSM-5 criteria for schizophrenia and schizoaffective disorder, and 63 were non-psychiatric comparison participants with no history of major mental illness. We assessed cognitive impairment using deficit scores, calculated based on performance (age- and sex-normed t-scores) on the MATRICS Consensus Cognitive Battery and Delis-Kaplan Executive Function System (DKEFS) for executive functioning. Domains of cognition assessed were executive functioning, processing speed, attention and vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. Schizophrenia symptom severity was assessed using the Scale for Assessment of Positive Symptoms (SAPS) and Scale for Assessment of Negative Symptoms (SANS). For psychiatric medication use, we examined daily dosage of antipsychotics, and whether the participant was taking anticholinergics. Chi-square, t-tests and logistic regressions were used to compare differences between impaired and non-impaired participants within NCs and PwS across all domains of cognition. Results Cognitive impairment was more frequent among PwS compared to NCs across all domains of cognition (Table 1). Among PwS, older age was associated with only processing speed impairment (p = 0.037). Female sex was associated with processing speed impairment (p = 0.018) and verbal memory impairment (p = 0.010) among PwS. Among NCs, older age (p = 0.036) was associated with only verbal memory impairment. In terms of schizophrenia-specific factors, higher antipsychotic dosages were associated with processing speed impairment (p = 0.019) and verbal memory impairment (p = 0.026). Anticholinergic use was associated with social cognitive impairment (p = 0.025). Conclusions Cognitive impairment is more severe and prevalent among PwS than among NCs, and risk factors differ between groups and across domains. Surprisingly, only among NCs was age associated with verbal memory impairment, while among PwS, age was associated with processing speed impairment. PwS have been observed to have both a neurodevelopmental and neurodegenerative pattern of decline, yet there may also be survivor effects where the older PwS in the sample are actually healthier and more cognitively impaired than PwS who did not survive to this age. Female sex was a risk factor for cognitive impairment only among PwS, possibly reflecting effects of sex hormones or sex differences in lifestyle. We found both antipsychotic and anticholinergic relationships with cognitive deficits - which is consistent with the risks associated with both of those medications. While these findings are preliminary, we plan to further investigate the context of our findings, examining key correlates of age and sex on other lifestyle risk factors (sleep, activity, diet) as well as more refined assessments of medication burden in this population. These findings may aid in screening efforts among PwS and guiding medication management to optimize healthy cognitive aging.

Cognitive Burden of Anticholinergic Medications in Psychotic Disorders

Genome-wide Association Study Accounting for Anticholinergic Burden to Examine Cognitive Dysfunction in Psychotic Disorders

Cardiovascular Pharmacogenomics and Cognitive Function in Patients with Schizophrenia

Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment in schizophrenia: results from the multicenter FACE-SZ cohort

Cross-Sectional Analysis of Cognitive Impairments and Associated Risk Factors among People with Schizophrenia

Polygenic risk for schizophrenia and measured domains of cognition in individuals with psychosis and controls

The effect of anticholinergic burden of psychiatric medications on major outcome domains of psychotic disorders: A 21-year prospective cohort study

Anticholinergic Burden and Cognitive Performance in Patients With Schizophrenia: A Systematic Literature Review

Metabolic risk factors of cognitive impairment in young women with major psychiatric disorder

Higher genetic risk of schizophrenia is associated with lower cognitive performance in healthy individuals

Deficits in Generalized Cognitive Ability, Visual Sensorimotor Function, and Inhibitory Control Represent Discrete Domains of Neurobehavioral Deficit in Psychotic Disorders.

M94. Genetic Analyses of Cognitive Performance in Psychotic Disorders from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) Consortium

The relationship of cardiovascular disease risk, clozapine antipsychotic use and cognitive function in a large Chinese schizophrenia cohort

Psychiatric symptoms, associated pharmacological treatments and cognitive function: A population-based study of men

Anticholinergic burden and cognitive functions in schizophrenia: a systematic literature review

Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease

Antipsychotic Drugs and Cognitive Function: A Systematic Review and Pairwise Network Meta-Analysis

Modeling the effects of treatment resistance and anticholinergic burden on cognitive function domains in patients with schizophrenia

Anticholinergic Medication Burden and Cognitive Subtypes in Parkinson's Disease without Dementia

Differential Effects of Different Antipsychotic Drugs on Cognitive Function in Patients with Chronic Schizophrenia

Medication and pharmacogenomic effects on cross-sectional symptom severity and cognitive ability in schizophrenia